Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers.

Nicole Bézay, Andrea Ayad,Katrin Dubischar,Christa Firbas,Romana Hochreiter,Sigrid Kiermayr,István Kiss,Fritz Pinl,Bernd Jilma,Kerstin Westritschnig

Vaccine（2016）

引用 65|浏览5

暂无评分

摘要

•A new vaccine candidate VLA84 to prevent CDI has been tested in a Phase I trial.•VLA84 was safe and well tolerated in healthy adult and healthy elderly volunteers.•VLA84 was highly immunogenic in adults and elderly.•IgG antibodies persisted at least 6 months after last immunization.•Functionality of IgG antibodies was shown in a T84 toxin neutralization assay.

查看译文

关键词

C. difficile,C. difficile vaccine,C. difficile associated diarrhoea (CDAD),C. difficile infection (CDI)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要